This panel provides drug-protein interaction and their ADRs along with references
| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| Ejaculation Disorder | Kappa-Type opioid receptor (P41145) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets
|
| Ejaculation Disorder | Neuropeptide S receptor (Q6W5P4) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets
|
| Erythematosus | N-acetyltransferase (P61599) | Erythematosus [ ADR Type 5 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW
|
| Gastric Fundal Mucosa | Neuropeptide Y (P01303) | a markedly enhanced output of NPY-LI then occurred upon nerve stimulation,which leads to the rat gastric fundal mucosa and reserpine ulcer [ ADR Type 1 ] | Neuropeptide Y and noradrenaline mechanisms in relation to reserpine induced impairment of sympathetic neurotransmission in the cat spleen
|
| Large Dense Core Vesicles | Carboxypeptidase (P16870) | Those of carboxypeptidase H and the alpha-amidating monooxygenase could only be determined in the paraventricular nucleus@which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Large Dense Core Vesicles | Chromaffin granule amine transporter (P54219) | Vesicular amine transporter was found in substantia nigra compacta@ the dorsal raphe and the locus coeruleus@which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Large Dense Core Vesicles | Chromogranin B (P05060) | Chromogranin B mRNA were increased in the dorsal raphe and in the substantia nigra compacta@which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides. [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Large Dense Core Vesicles | Peptidyl-glycine alpha-amidating monooxygenase (P19021) | Those of carboxypeptidase H and the alpha-amidating monooxygenase could only be determined in the paraventricular nucleus@which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides. [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Large Dense Core Vesicles | Secretogranin-2 (P20616) | Secretogranin II message was elevated in the parvocellular neurons of the paraventricular cleus@which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Large Dense Core Vesicles | Synaptin (P00055) | Messages for synaptin/synaptophysin could be found in most of the nuclei investigated,which stimulated neurons and leads to an increased synthesis of secretory peptides and consequently to large dense core vesicles filled with higher quanta of peptides. [ ADR Type 1 ] | Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synaptin/synaptophys
|
| Nasal Congestion | Kappa-Type opioid receptor (P41145) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets
|
| Ulcer | Adenylate cyclase (Q08828) | Before the appearance of reserpine ulcer@ significant changes in the feedback mechanism system@ i e between the ATP--membrane ATPase--ADP and the ATP--adenylate cyclase--cAMP energy systems@ can be observed in the rat gastric fundal mucosa [ ADR Type 2 ] | Cellular energy systems and reserpine ulcer in rats
|
| Ulcer | Sodium/potassium-transporting ATPase (P05023) | Before the appearance of reserpine ulcer@ significant changes in the feedback mechanism system@ i.e. between the ATP--membrane ATPase--ADP and the ATP--adenylate cyclase--cAMP energy systems@ can be observed in the rat gastric fundal mucosa. [ ADR Type 2 ] | Cellular energy systems and reserpine ulcer in rats
|